These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 23022285)

  • 21. Disruption of the Fgf2 gene activates the adipogenic and suppresses the osteogenic program in mesenchymal marrow stromal stem cells.
    Xiao L; Sobue T; Esliger A; Kronenberg MS; Coffin JD; Doetschman T; Hurley MM
    Bone; 2010 Aug; 47(2):360-70. PubMed ID: 20510392
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Thiazolidinediones and skeletal health].
    Meier C; Bodmer M; Meier CR; Kraenzlin ME
    Rev Med Suisse; 2009 Jun; 5(207):1309-10, 1312-3. PubMed ID: 19626930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thiazolidinedione-induced lipid droplet formation during osteogenic differentiation.
    van de Vyver M; Andrag E; Cockburn IL; Ferris WF
    J Endocrinol; 2014 Nov; 223(2):119-32. PubMed ID: 25210048
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The omega-6 arachidonic fatty acid, but not the omega-3 fatty acids, inhibits osteoblastogenesis and induces adipogenesis of human mesenchymal stem cells: potential implication in osteoporosis.
    Casado-Díaz A; Santiago-Mora R; Dorado G; Quesada-Gómez JM
    Osteoporos Int; 2013 May; 24(5):1647-61. PubMed ID: 23104199
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thiazolidinediones, cardiovascular disease and cardiovascular mortality: translating research into action for diabetes (TRIAD).
    Bilik D; McEwen LN; Brown MB; Selby JV; Karter AJ; Marrero DG; Hsiao VC; Tseng CW; Mangione CM; Lasser NL; Crosson JC; Herman WH
    Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):715-21. PubMed ID: 20583206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel thiazolidinedione analog reduces a negative impact on bone and mesenchymal stem cell properties in obese mice compared to classical thiazolidinediones.
    Benova A; Ferencakova M; Bardova K; Funda J; Prochazka J; Spoutil F; Cajka T; Dzubanova M; Balcaen T; Kerckhofs G; Willekens W; van Lenthe GH; Alquicer G; Pecinova A; Mracek T; Horakova O; Rossmeisl M; Kopecky J; Tencerova M
    Mol Metab; 2022 Nov; 65():101598. PubMed ID: 36103974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dexamethasone shifts bone marrow stromal cells from osteoblasts to adipocytes by C/EBPalpha promoter methylation.
    Li J; Zhang N; Huang X; Xu J; Fernandes JC; Dai K; Zhang X
    Cell Death Dis; 2013 Oct; 4(10):e832. PubMed ID: 24091675
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.
    Wang CC; Chen WL; Kao TW; Chang YW; Loh CH; Chou CC
    Clin Ther; 2011 Dec; 33(12):1904-13. PubMed ID: 22118894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes.
    Aubert RE; Herrera V; Chen W; Haffner SM; Pendergrass M
    Diabetes Obes Metab; 2010 Aug; 12(8):716-21. PubMed ID: 20590749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Androgens and estrogens prevent rosiglitazone-induced adipogenesis in human mesenchymal stem cells.
    Benvenuti S; Cellai I; Luciani P; Deledda C; Saccardi R; Mazzanti B; Dal Pozzo S; Serio M; Peri A
    J Endocrinol Invest; 2012 Apr; 35(4):365-71. PubMed ID: 21597316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Osteoanabolic effect of alendronate and zoledronate on bone marrow stromal cells (BMSCs) isolated from aged female osteoporotic patients and its implications for their mode of action in the treatment of age-related bone loss.
    Lindtner RA; Tiaden AN; Genelin K; Ebner HL; Manzl C; Klawitter M; Sitte I; von Rechenberg B; Blauth M; Richards PJ
    Osteoporos Int; 2014 Mar; 25(3):1151-61. PubMed ID: 23974861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of TZD Use and Discontinuation on Fracture Rates in ACCORD Bone Study.
    Schwartz AV; Chen H; Ambrosius WT; Sood A; Josse RG; Bonds DE; Schnall AM; Vittinghoff E; Bauer DC; Banerji MA; Cohen RM; Hamilton BP; Isakova T; Sellmeyer DE; Simmons DL; Shibli-Rahhal A; Williamson JD; Margolis KL
    J Clin Endocrinol Metab; 2015 Nov; 100(11):4059-66. PubMed ID: 26305617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MCP-1 Feedback Loop Between Adipocytes and Mesenchymal Stromal Cells Causes Fat Accumulation and Contributes to Hematopoietic Stem Cell Rarefaction in the Bone Marrow of Patients With Diabetes.
    Ferland-McCollough D; Maselli D; Spinetti G; Sambataro M; Sullivan N; Blom A; Madeddu P
    Diabetes; 2018 Jul; 67(7):1380-1394. PubMed ID: 29703845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of Adipogenic Differentiation of Human Bone Marrow-Derived Mesenchymal Stem Cells by a Phytoestrogen Diarylheptanoid from
    Sutjarit N; Thongon N; Weerachayaphorn J; Piyachaturawat P; Suksamrarn A; Suksen K; Papachristou DJ; Blair HC
    J Agric Food Chem; 2020 Sep; 68(37):9993-10002. PubMed ID: 32838526
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of the antidiabetic agent pioglitazone on bone metabolism in rats.
    Kanda J; Izumo N; Kobayashi Y; Onodera K; Shimakura T; Yamamoto N; Takahashi HE; Wakabayashi H
    J Pharmacol Sci; 2017 Sep; 135(1):22-28. PubMed ID: 28928054
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial.
    Punthakee Z; Bosch J; Dagenais G; Diaz R; Holman R; Probstfield J; Ramachandran A; Riddle M; Rydén LE; Zinman B; Afzal R; Yusuf S; Gerstein H;
    Diabetologia; 2012 Jan; 55(1):36-45. PubMed ID: 22038523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diabetes and skeletal health.
    Yaturu S
    J Diabetes; 2009 Dec; 1(4):246-54. PubMed ID: 20923525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone).
    Sottile V; Seuwen K; Kneissel M
    Calcif Tissue Int; 2004 Oct; 75(4):329-37. PubMed ID: 15549648
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thiazolidinedione use and the risk of fractures.
    Toulis KA; Goulis DG; Anastasilakis AD
    CMAJ; 2009 Apr; 180(8):841-2; author reply 842-3. PubMed ID: 19364796
    [No Abstract]   [Full Text] [Related]  

  • 40. Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.
    Lu CJ; Sun Y; Muo CH; Chen RC; Chen PC; Hsu CY
    Cerebrovasc Dis; 2013; 36(2):145-51. PubMed ID: 24029780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.